[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eisbach Bio GmbH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100556453",false,"NCT06525298","EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","A Phase 1\u002F2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors","Inclusion Criteria:\n\n* Recurrent locally advanced or metastatic solid tumors\n* Homologous recombination deficient mutations\n* Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy\n* Measurable disease (RECIST 1.1 Criteria)\n* Adequate organ and bone marrow function\n* ECOG Performance Status 0 or 1\n* Life expectancy \\> 3 months\n\nExclusion Criteria:\n\n* History or evidence of any clinically relevant gastrointestinal disease\n* Radiation therapy within ≤2 weeks\n* Significant cardiovascular disease\n* Uncontrolled, active, symptomatic brain metastases","ALL","18 Years",{"count":18,"type":19},144,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).",[26,27,28],"Advanced Solid Tumor","Homologous Recombination Deficiency","HRR Deficiency","RECRUITING","2024-09-14",{"date":32,"type":33},"2024-09-19","ACTUAL",{"date":35,"type":33},"2024-09-09",{"date":37,"type":19},"2027-12",{"name":39,"class":40},"Eisbach Bio GmbH","INDUSTRY",""]